Saratov JOURNAL of Medical and Scientific Research
Home

Skin autofluorescence parameter as an adverse prognosis factor in patients with peripheral forms of atherosclerosis

Year: 2022, volume 18 Issue: №4 Pages: 568-575
Heading: Cardiology Article type: Original article
Authors: Davydova N.A., Lebedev P.A., Ayupov A.M., Kornilin D.V., Grishanov V.N., Komarova M.V.
Organization: Samara National Research University, Samara Regional Clinical Hospital n. a. V. D. Seredavin, Samara State Medical University
Summary:

Abstract. Objective: prognostic significance determination of skin autofluorescence (SAF) as a factor of mortality and cardiovascular complications. Material and methods. We undertook the prospective study included 122 patients with peripheral arterial disease (PAD): stenotic atherosclerosis of the brachio-cephalic trunk was revealed in 95 (77.9%), chronic arterial insufficiency of the lower extremities (CAI) in 47 (38.5%). SAF parameter was determined using an original device developed by the authors. Clinical, anthro-pometric, biochemical as well as instrumental parameters of heart and vessels were studied by ultrasound investigation methods. The prospective part was carried out at periods of up to 1043 days (mean 736 days). Results. SAF parameter was positively and significantly correlated with the scores on the scale of clinical prognostic signs, with CAI, the fact of operations on the leg arteries. There were 7 fatal cases and at least one hospitalization for cardiovascular reasons in 42 patients during the observation period. The most frequent were hospitalizations for conservative treatment of PAD, the need for aortocoronary bypass grafting and coronary artery stenting. The method of logistic regression determined that the fact of hospitalization or mortality was associated with SAF and blood plasma glucose, the presence of chronic heart failure above functional class 1. Model parameters: sensitivity 71 %, specificity 68%. Conclusion. SAF parameter can be used as an integral independent predictor in patients with multifocal atherosclerosis.

Keywords: peripheral atherosclerosis, skin autofluorescence

Bibliography:
1. Scully RE, Arnaoutakis DJ, DeBord Smith A, et al. Estimated annual health care expenditures in individuals with peripheral arterial disease. J Vase Surg. 2018; 67 (2): 558-67. DOI: 10.1016/j.jvs.2017.06.102.
2. Aboyans V, Ricco J-B, Bartelink M-LEL, et al. 2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur Heart J. 2017; (2017): 1-60. DOI: 10.1093/eurheartj/ehx095.
3. Sigvant B, Wiberg-Hedman K, Bergqvist D, et al. A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences. J Vase Surg. 2007; 45 (6): 1185-91. DOI: 10.1016/j.jvs.2007.02.004.
4. Kanauchi M, Tsujimoto N, Hashimoto T. Advanced glycation end products in nondiabetic patients with coronary artery disease. Diabetes Care. 2001; 24 (9): 1620-3. DOI: 10.2337/diacare.24.9.1620.
5. Hofmann B, Jacobs K, Navarrete Santos A, et al. Relationship between cardiac tissue glycation and skin autofluores-cence in patients with coronary artery disease. Diabetes Metab. 2015; 41 (5): 410-5. DOI: 10.1016/j.diabet.2014.12.001.
6. Kornilin DV, Grishanov VN, Cherepanov KV Pulse excitation fluorescence meter for diagnostic purposes. Proc. SPIE 10685, Biophotonics: Photonic Solutions for Better Health Care VI, 1068515. URL: https://spie.org/Publications/Procee-dings/Paper/10.1117/12.2306588?SSO=1 (10 Oct 2022). DOI: 10.1117/12.2306588.
7. Aboyans V, Ricco JB, Bartelink MEL, et al. ECS Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). 2017. Russ J Cardiol. 2018; 23 (8): 164-221
8. Fowkes FG, Aboyans V, Fowkes FJI, et al. Peripheral artery disease: epidemiology and global perspectives. Nat Rev Cardiol. 2017; 14(3): 156-70. DOI: 10.1038/nrcardio.2016.179.
9. Feringa HH, Bax JJ, Hoeks S, et al. A prognostic risk index for long-term mortality in patients with peripheral arterial disease. Arch Intern Med. 2007; 167 (22): 2482-9. DOI: 10.1001/archinte. 167.22.2482.
10. Jang SY, Park SW, Kim YW, et al. Survival rates in peripheral artery disease. J Lipid Atheroscler. 2017; 6 (1): 39-45. DOI: 10.12997/jla.2017.6.1.39.
11. Zhang Y, Jiang T, Liu C, et al. Effectiveness of early advanced glycation end product accumulation testing in the diagnosis of diabetes: a health risk factor analysis using the body mass index as a moderator. Front Endocrinol (Lausanne). 2022; (12): 766778. DOI: 10.3389/fendo.2021.766778.
12. Lutgers HL, Gerrits EG, Graaff R, et al. Skin autofluores-cence provides additional informationto the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia. 2009; 52 (5): 789-97. DOI: 10.1007/s00125-009-1308-9.
13. Hu H, Jiang H, Zhu L, et al. Accumulation of advanced glycation end products and subclinical inflammation in deep tissues of adult patients with and without diabetes. Can J Diabetes. 2018; 42 (5): 525-32. e4. DOI: 10.1016/j.jcjd.2018.01.003.
14. Cavero-Redondo I, Soriano-Cano A, Alvarez-Bueno C, et al. Skin autofluorescence-indicated advanced glycation end products as predictors of cardiovascular and all-cause mortality in high-risk subjects: A systematic review and meta-analysis. J Am Heart Assoc. 2018; 7 (18): e009833. DOI: 10.1161/JAHA. 118.009833.
15. deVos LC, Noordzij MJ, Mulder DJ, et al. Skin auto-fluorescence as a measure of advanced glycation end products deposition is elevated in peripheral artery disease. Arterioscler Thromb Vase Biol. 2013; 33 (1): 131-8. DOI: 10.1161 /ATVBAHA. 112.300016.
16. de Vos LC, Mulder DJ, Smit AJ, et al. Skin autofluores-cence is associated with 5-year mortality and cardiovascular events in patients with peripheral artery disease. Arterioscler Thromb Vase Biol. 2014; 34(4): 933-8. DOI: 10.1161/ATVBAHA. 113.302731.
17. Bays HE, KulkarniA, German C, etal. Ten things to know about ten cardiovascular disease risk factors — 2022. Am J Prev Cardiol. 2022; (10): 100342. DOI: 10.1016/j.ajpc.2022.100342.
18. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020; 41 (2): 255-323. DOI: 10.1093/eurheartj/ehz486.
19. Clemens RK, Annema W, Baumann F, et al. Cardiac biomarkers but not measures of vascular atherosclerosis predict mortality in patients with peripheral artery disease. Clin Chim Acta. 2019; (495): 215-20. DOI: 10.1016/j.cca.2019.04.061.
20. SkrzypekA, Mostowik M, Szeliga M, et al. Chronic heart failure in the elderly: still a current medical problem. Folia Med Cracov. 2018; 58 (4): 47-56.

AttachmentSize
2022_4_568-575.pdf582.72 KB
All articles of the authors: Ayupov A.M., Davydova N.A., Grishanov V.N., Komarova M.V. , Kornilin D.V., Lebedev P.A.

No votes yet